Despite promising clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant difficulty from PBMs. Such insurers are frequently creating https://laytnyghz246830.topbloghub.com/48622679/the-vyndamax-faces-is-meeting-pbm-obstacles-the-look-at-reimbursement-battles